These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1796983)

  • 21. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome.
    Festen DA; Wevers M; Lindgren AC; Böhm B; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):919-25. PubMed ID: 18031326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood.
    Coupaye M; Lorenzini F; Lloret-Linares C; Molinas C; Pinto G; Diene G; Mimoun E; Demeer G; Labrousse F; Jauregi J; Laurier V; Basdevant A; Polak M; Thuilleaux D; Tauber M; Poitou C
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E328-35. PubMed ID: 23284006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prader-Willi syndrome: A case report].
    Ma HW; Dai XM
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Dec; 8(6):521-3. PubMed ID: 17178054
    [No Abstract]   [Full Text] [Related]  

  • 24. Retrospective study of the potential benefits and adverse events during growth hormone treatment in children with Prader-Willi syndrome.
    Fillion M; Deal C; Van Vliet G
    J Pediatr; 2009 Feb; 154(2):230-3. PubMed ID: 18814886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
    Lindgren AC; Lindberg A
    Horm Res; 2008; 70(3):182-7. PubMed ID: 18663319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early manifestations of Prader-Willi syndrome: influence of growth hormone.
    Eiholzer U; Schlumpf M; Nordmann Y; l'Allemand D
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1441-4. PubMed ID: 11837497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of recombinant human growth hormone treatment in intrauterine growth-retarded preterm newborn infant on growth, body composition and energy expenditure.
    van Toledo-Eppinga L; Houdijk EC; Cranendonk A; Delemarre-Van de Waal HA; Lafeber HN
    Acta Paediatr; 1996 Apr; 85(4):476-81. PubMed ID: 8740309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adults with Prader-Willi syndrome have weaker bones: effect of treatment with GH and sex steroids.
    Longhi S; Grugni G; Gatti D; Spinozzi E; Sartorio A; Adami S; Fanolla A; Radetti G
    Calcif Tissue Int; 2015 Feb; 96(2):160-6. PubMed ID: 25577526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body composition during GH treatment in Prader-Labhardt-Willi syndrome.
    Bosio L; Beccaria L; Benzi F; Sanzari A; Chiumello G
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():351-3. PubMed ID: 10698601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac tamponade due to systemic lupus erythematosus in patient with Prader-Willi syndrome after growth hormone therapy.
    Kuramochi Y; Kato T; Sudou M; Sugano H; Takagi H; Morita T
    Lupus; 2007; 16(6):447-9. PubMed ID: 17664237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition.
    Höybye C
    Acta Paediatr; 2015 Apr; 104(4):422-7. PubMed ID: 25557351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
    Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects on growth and metabolism of growth hormone treatment for 3 years in 36 children with Prader-Willi syndrome.
    Colmenares A; Pinto G; Taupin P; Giuseppe A; Odent T; Trivin C; Laborde K; Souberbielle JC; Polak M
    Horm Res Paediatr; 2011 Feb; 75(2):123-30. PubMed ID: 20847547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sudden death in Prader-Willi syndrome during growth hormone therapy.
    Sacco M; Di Giorgio G
    Horm Res; 2005; 63(1):29-32. PubMed ID: 15583479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between foot growth and musculoskeletal loading in children with Prader-Willi syndrome before and during growth hormone treatment.
    Eiholzer U; Meinhardt U; Gallo C; Schlumpf M; Rousson V; l'Allemand D
    J Pediatr; 2009 Feb; 154(2):225-9. PubMed ID: 18822426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using stable isotopes to assess reduced physical activity of individuals with Prader-Willi syndrome.
    Davies PS; Joughin C
    Am J Ment Retard; 1993 Nov; 98(3):349-53. PubMed ID: 8292311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome.
    Haqq AM; Stadler DD; Rosenfeld RG; Pratt KL; Weigle DS; Frayo RS; LaFranchi SH; Cummings DE; Purnell JQ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3573-6. PubMed ID: 12915638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.